TY  - JOUR
AU  - Krajnović, Milena M.
AU  - Marković, Bojana
AU  - Knežević-Ušaj, Slavica
AU  - Nikolic, Ivan
AU  - Stanojevic, Maja
AU  - Nikolić, Valentina
AU  - Siljic, Marina
AU  - Jovanović-Ćupić, Snežana P.
AU  - Dimitrijević, Bogomir B.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1164
AB  - In this study, we investigated the mutation status of KRAS gene in pretherapeutic and preoperative biopsies in 63 specimens of locally advanced rectal cancers in order to evaluate its potential predictive and/or prognostic role. Regions of interest of KRAS exon 2 were amplified and visualized on 2% agarose gel. Obtained PCR products were subjected to direct sequencing. KRAS mutations were detected in 35% of patients, 91% of which were located in codon 12 and 9% in codon 13. In general, KRAS mutation status did not affect the response to neoadjuvant chemoradiotherapy (CRT). However, patients harboring mutated KRAS gene, simultaneously with high vascular endothelial growth factor (VEGF) expression, exhibited a worse response to CRT (p = 0.030), a more frequent appearance of local recurrences and distant metastasis (p = 0.003), and shorter overall survival (p = 0.001) compared to all others. On the contrary, patients with GGT GT GCT KRAS mutation exhibited a significantly better response to CRT than those with any other type of KRAS mutation (p = 0.017). Moreover, the presence of GGT GT GCT mutation was associated with low VEGF and Ki67 expression (p = 0.012 in both cases), parameters related to less aggressiveness of the disease. Our results suggest that KRAS mutation status could have some predictive and prognostic importance in rectal cancer when analyzed together with other parameters, such as VEGF and Ki67 expression. In addition, it seems that not only the presence but the type of KRAS mutation is important for examining its impact on CRT response. (C) 2016 Elsevier GmbH. All rights reserved.
T2  - Pathology Research and Practice
T1  - Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics
VL  - 212
IS  - 7
SP  - 598
EP  - 603
DO  - 10.1016/j.prp.2016.02.018
ER  - 

@article{
author = "Krajnović, Milena M. and Marković, Bojana and Knežević-Ušaj, Slavica and Nikolic, Ivan and Stanojevic, Maja and Nikolić, Valentina and Siljic, Marina and Jovanović-Ćupić, Snežana P. and Dimitrijević, Bogomir B.",
year = "2016",
abstract = "In this study, we investigated the mutation status of KRAS gene in pretherapeutic and preoperative biopsies in 63 specimens of locally advanced rectal cancers in order to evaluate its potential predictive and/or prognostic role. Regions of interest of KRAS exon 2 were amplified and visualized on 2% agarose gel. Obtained PCR products were subjected to direct sequencing. KRAS mutations were detected in 35% of patients, 91% of which were located in codon 12 and 9% in codon 13. In general, KRAS mutation status did not affect the response to neoadjuvant chemoradiotherapy (CRT). However, patients harboring mutated KRAS gene, simultaneously with high vascular endothelial growth factor (VEGF) expression, exhibited a worse response to CRT (p = 0.030), a more frequent appearance of local recurrences and distant metastasis (p = 0.003), and shorter overall survival (p = 0.001) compared to all others. On the contrary, patients with GGT GT GCT KRAS mutation exhibited a significantly better response to CRT than those with any other type of KRAS mutation (p = 0.017). Moreover, the presence of GGT GT GCT mutation was associated with low VEGF and Ki67 expression (p = 0.012 in both cases), parameters related to less aggressiveness of the disease. Our results suggest that KRAS mutation status could have some predictive and prognostic importance in rectal cancer when analyzed together with other parameters, such as VEGF and Ki67 expression. In addition, it seems that not only the presence but the type of KRAS mutation is important for examining its impact on CRT response. (C) 2016 Elsevier GmbH. All rights reserved.",
journal = "Pathology Research and Practice",
title = "Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics",
volume = "212",
number = "7",
pages = "598-603",
doi = "10.1016/j.prp.2016.02.018"
}

Krajnović, M. M., Marković, B., Knežević-Ušaj, S., Nikolic, I., Stanojevic, M., Nikolić, V., Siljic, M., Jovanović-Ćupić, S. P.,& Dimitrijević, B. B.. (2016). Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. in Pathology Research and Practice, 212(7), 598-603.
https://doi.org/10.1016/j.prp.2016.02.018

Krajnović MM, Marković B, Knežević-Ušaj S, Nikolic I, Stanojevic M, Nikolić V, Siljic M, Jovanović-Ćupić SP, Dimitrijević BB. Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. in Pathology Research and Practice. 2016;212(7):598-603.
doi:10.1016/j.prp.2016.02.018 .

Krajnović, Milena M., Marković, Bojana, Knežević-Ušaj, Slavica, Nikolic, Ivan, Stanojevic, Maja, Nikolić, Valentina, Siljic, Marina, Jovanović-Ćupić, Snežana P., Dimitrijević, Bogomir B., "Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics" in Pathology Research and Practice, 212, no. 7 (2016):598-603,
https://doi.org/10.1016/j.prp.2016.02.018 . .

TY  - JOUR
AU  - Jovanović-Ćupić, Snežana P.
AU  - Glišić, Sanja
AU  - Stanojevic, Maja
AU  - Nozic, Darko
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Krajnović, Milena M.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1032
AB  - The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p LT 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p LT 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p LT 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.
PB  - Springer
T2  - Archives of Virology
T1  - The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia
VL  - 161
IS  - 5
SP  - 1189
EP  - 1198
DO  - 10.1007/s00705-016-2777-z
ER  - 

@article{
author = "Jovanović-Ćupić, Snežana P. and Glišić, Sanja and Stanojevic, Maja and Nozic, Darko and Petrović, Nina and Mandušić, Vesna and Krajnović, Milena M.",
year = "2016",
abstract = "The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p LT 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p LT 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p LT 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.",
publisher = "Springer",
journal = "Archives of Virology",
title = "The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia",
volume = "161",
number = "5",
pages = "1189-1198",
doi = "10.1007/s00705-016-2777-z"
}

Jovanović-Ćupić, S. P., Glišić, S., Stanojevic, M., Nozic, D., Petrović, N., Mandušić, V.,& Krajnović, M. M.. (2016). The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia. in Archives of Virology
Springer., 161(5), 1189-1198.
https://doi.org/10.1007/s00705-016-2777-z

Jovanović-Ćupić SP, Glišić S, Stanojevic M, Nozic D, Petrović N, Mandušić V, Krajnović MM. The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia. in Archives of Virology. 2016;161(5):1189-1198.
doi:10.1007/s00705-016-2777-z .

Jovanović-Ćupić, Snežana P., Glišić, Sanja, Stanojevic, Maja, Nozic, Darko, Petrović, Nina, Mandušić, Vesna, Krajnović, Milena M., "The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia" in Archives of Virology, 161, no. 5 (2016):1189-1198,
https://doi.org/10.1007/s00705-016-2777-z . .

TY  - JOUR
AU  - Senćanski, Milan V.
AU  - Radošević, Draginja
AU  - Perović, Vladimir R.
AU  - Gemović, Branislava S.
AU  - Stanojevic, Maja
AU  - Veljković, Nevena V.
AU  - Glišić, Sanja
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/806
AB  - The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.
T2  - Current Pharmaceutical Design
T1  - Natural Products as Promising Therapeutics for Treatment of Influenza Disease
VL  - 21
IS  - 38
SP  - 5573
EP  - 5588
DO  - 10.2174/1381612821666151002113426
ER  - 

@article{
author = "Senćanski, Milan V. and Radošević, Draginja and Perović, Vladimir R. and Gemović, Branislava S. and Stanojevic, Maja and Veljković, Nevena V. and Glišić, Sanja",
year = "2015",
abstract = "The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.",
journal = "Current Pharmaceutical Design",
title = "Natural Products as Promising Therapeutics for Treatment of Influenza Disease",
volume = "21",
number = "38",
pages = "5573-5588",
doi = "10.2174/1381612821666151002113426"
}

Senćanski, M. V., Radošević, D., Perović, V. R., Gemović, B. S., Stanojevic, M., Veljković, N. V.,& Glišić, S.. (2015). Natural Products as Promising Therapeutics for Treatment of Influenza Disease. in Current Pharmaceutical Design, 21(38), 5573-5588.
https://doi.org/10.2174/1381612821666151002113426

Senćanski MV, Radošević D, Perović VR, Gemović BS, Stanojevic M, Veljković NV, Glišić S. Natural Products as Promising Therapeutics for Treatment of Influenza Disease. in Current Pharmaceutical Design. 2015;21(38):5573-5588.
doi:10.2174/1381612821666151002113426 .

Senćanski, Milan V., Radošević, Draginja, Perović, Vladimir R., Gemović, Branislava S., Stanojevic, Maja, Veljković, Nevena V., Glišić, Sanja, "Natural Products as Promising Therapeutics for Treatment of Influenza Disease" in Current Pharmaceutical Design, 21, no. 38 (2015):5573-5588,
https://doi.org/10.2174/1381612821666151002113426 . .

TY  - JOUR
AU  - Jovanović-Ćupić, Snežana P.
AU  - Glišić, Sanja
AU  - Stanojevic, M.
AU  - Vasiljević, N.
AU  - Bojić, Tijana
AU  - Božović, Ana M.
AU  - Dimitrijević, Bogomir B.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5858
AB  - Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patients likelihood Of achieving sustained viral response.
T2  - Archives of Biological Sciences
T1  - Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b
VL  - 66
IS  - 1
SP  - 193
EP  - 201
DO  - 10.2298/ABS1401193J
ER  - 

@article{
author = "Jovanović-Ćupić, Snežana P. and Glišić, Sanja and Stanojevic, M. and Vasiljević, N. and Bojić, Tijana and Božović, Ana M. and Dimitrijević, Bogomir B.",
year = "2014",
abstract = "Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patients likelihood Of achieving sustained viral response.",
journal = "Archives of Biological Sciences",
title = "Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b",
volume = "66",
number = "1",
pages = "193-201",
doi = "10.2298/ABS1401193J"
}

Jovanović-Ćupić, S. P., Glišić, S., Stanojevic, M., Vasiljević, N., Bojić, T., Božović, A. M.,& Dimitrijević, B. B.. (2014). Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b. in Archives of Biological Sciences, 66(1), 193-201.
https://doi.org/10.2298/ABS1401193J

Jovanović-Ćupić SP, Glišić S, Stanojevic M, Vasiljević N, Bojić T, Božović AM, Dimitrijević BB. Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b. in Archives of Biological Sciences. 2014;66(1):193-201.
doi:10.2298/ABS1401193J .

Jovanović-Ćupić, Snežana P., Glišić, Sanja, Stanojevic, M., Vasiljević, N., Bojić, Tijana, Božović, Ana M., Dimitrijević, Bogomir B., "Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b" in Archives of Biological Sciences, 66, no. 1 (2014):193-201,
https://doi.org/10.2298/ABS1401193J . .

TY  - JOUR
AU  - Davidović, Radoslav S.
AU  - Sopta, Jelena
AU  - Mandušić, Vesna
AU  - Krajnović, Milena M.
AU  - Stanojevic, Maja
AU  - Tulic, Goran
AU  - Dimitrijević, Bogomir B.
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5646
AB  - Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53-p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16(INK4a)/p14(ARF) genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14(ARF) gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14(ARF) promoter. The results from the current study suggest significant impact of the p14(ARF) gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53-p14 and Rb-p16 pathways in liposarcoma.
T2  - Medical Oncology
T1  - p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma
VL  - 30
IS  - 3
DO  - 10.1007/s12032-013-0682-9
ER  - 

@article{
author = "Davidović, Radoslav S. and Sopta, Jelena and Mandušić, Vesna and Krajnović, Milena M. and Stanojevic, Maja and Tulic, Goran and Dimitrijević, Bogomir B.",
year = "2013",
abstract = "Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53-p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16(INK4a)/p14(ARF) genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14(ARF) gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14(ARF) promoter. The results from the current study suggest significant impact of the p14(ARF) gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53-p14 and Rb-p16 pathways in liposarcoma.",
journal = "Medical Oncology",
title = "p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma",
volume = "30",
number = "3",
doi = "10.1007/s12032-013-0682-9"
}

Davidović, R. S., Sopta, J., Mandušić, V., Krajnović, M. M., Stanojevic, M., Tulic, G.,& Dimitrijević, B. B.. (2013). p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma. in Medical Oncology, 30(3).
https://doi.org/10.1007/s12032-013-0682-9

Davidović RS, Sopta J, Mandušić V, Krajnović MM, Stanojevic M, Tulic G, Dimitrijević BB. p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma. in Medical Oncology. 2013;30(3).
doi:10.1007/s12032-013-0682-9 .

Davidović, Radoslav S., Sopta, Jelena, Mandušić, Vesna, Krajnović, Milena M., Stanojevic, Maja, Tulic, Goran, Dimitrijević, Bogomir B., "p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma" in Medical Oncology, 30, no. 3 (2013),
https://doi.org/10.1007/s12032-013-0682-9 . .